
    
      If a patient qualifies for participation in an ongoing niraparib clinical trial or is already
      participating in a niraparib clinical trial, she will not be able to participate in the EAP.

      Ongoing clinical trials for niraparib include:

        -  A Phase 3 trial in patients who have received first-line treatment for ovarian cancer
           (the PRIMA trial, NCT # 02655016)

        -  A Phase 2 trial in patients who have received multiple lines of treatment for ovarian
           cancer (the QUADRA trial, NCT # 02354586)

        -  A Phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer
           or recurrent ovarian cancer. (the TOPACIO trial, NCT # 02657889)
    
  